Insights Into Treatment-Resistant Depression:  Current and Emerging Therapies | Ask the experts:  James Murrough, MD, PhD  |  Psychiatry Advisor

#MedicalProfessionals #MentalHealth #Psychiatry  #PsychiatryAdvisor  #CurrentTherapies  #EmergingTherapies

Insights Into Treatment-Resistant Depression:  Current and Emerging Therapies | Ask the experts:  James Murrough, MD, PhD  |  Psychiatry Advisor 

Questions:

  1. Why are high rates of partial or inadequate responses to first-line antidepressant therapy seen in patients with major depressive disorder (MDD)?
  2. What are the risks associated with partial or inadequate MDD treatment?
  3. What are the current challenges associated with treating patients with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs)?
  4. Can you discuss the potential therapeutic role of modulating pathways outside of the monoamine oxidase pathway in MDD? This may include opioidergic, ionotropic, and metabotropic glutamatergic receptor modulation.
  5. Can you briefly review your general treatment algorithms for patients with treatment-resistant depression?

 

Read James Murrough’s, MD, PhD answers via this link  >>>

Quoted from end of article  >>> 
Insights Into Treatment-Resistant Depression:  Current and Emerging Therapies
Disclosures: Dr Murrough has provided consultation or scientific advisory services to Allergan, Novartis, Fortress Biotech, Janssen, Medavante-Prophase, and Global Medical Education.

Visit Psychiatry Advisor for more readables aimed at PROFESSIONALS  >>>